
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 14, 2015

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

0-26224
(Commission
File Number)

51-0317849
(I.R.S. Employer
Identification No.)

311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On January 14, 2015, the United States Food and Drug Administration (the “FDA”) issued a letter to Integra LifeSciences Corporation, a wholly-owned subsidiary of Integra LifeSciences Holdings Corporation (the “Company”) informing the Company that it had addressed the violations in the FDA warning letter dated February 13, 2013 related to the Company’s medical devices manufacturing facility in Añasco, Puerto Rico (the “Añasco Facility”) and that such warning letter had been closed out effective January 14, 2015. A copy of the letter dated January 14, 2015 relating to the resolution of the warning letter matters is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The press release issued by the Company on January 20, 2015 announcing the resolution of the FDA warning letter related to the Añasco Facility is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits**

- 99.1 Letter, dated January 14, 2015, from the United States Food and Drug Administration to Integra LifeSciences Corporation
- 99.2 Press release issued January 20, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: January 20, 2015

By: /s/ Glenn G. Coleman

Glenn G. Coleman

Title: Corporate Vice President and Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Exhibit</u>
99.1	Letter, dated January 14, 2015, from the United States Food and Drug Administration to Integra LifeSciences Corporation
99.2	Press release issued January 20, 2015



DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Food and Drug Administration
466 Fernandez Juncos Avenue
San Juan, Puerto Rico, 00901
Telephone: 787-729-8500
FAX: 787-729-8826

January 14, 2015

15-SJN-WLCOL-03

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Mr. Peter Arduini
President and CEO
Integra Life-Sciences Corporation
311 Enterprise Drive,
Plainsboro, N.J. 08536

Dear Mr. Arduini:

We have completed an evaluation of your firm's corrective actions in response to our Warning Letter 13-SJN-WL-03 dated February 13, 2013. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Should you have questions and/or comments regarding this matter, please feel free to contact me at the district office address provided in the letterhead. You may also contact Mrs. Margarita Santiago, Compliance Officer at telephone number (787) 729-8702 or at margarita.santiago@fda.hhs.gov.

Kind regards,

A handwritten signature in black ink, appearing to read "Edwin Ramos", written in a cursive style.

Edwin Ramos
Director of Compliance
San Juan District Office

A handwritten signature in black ink, consisting of several loops and a final downward stroke, positioned above a horizontal line.

Reviewed by: _____

Date: _____ 1/14/15

CB: WL Legal File
FEI: 3000204775
CMS Case: 392719

News Release

Contacts:

Integra LifeSciences Holdings Corporation

Investor Relations:

Angela Steinway

(609) 936-2268

angela.steinway@integralife.com

***Integra LifeSciences Announces Resolution of Warning Letter
Related to its Manufacturing Facility in Añasco, Puerto Rico***

Plainsboro, New Jersey / January 20, 2015 – Integra LifeSciences Holdings Corporation (NASDAQ: IART - news) today announced the United States Food and Drug Administration (the “FDA”) has informed the Company that it had addressed the violations in the warning letter relating to its manufacturing facility in Añasco, Puerto Rico (the “Añasco” facility).

The Añasco facility had been operating subject to an FDA Warning Letter dated February 13, 2013 that related to quality systems issues. After concluding its recent inspection of the Añasco facility in September 2014, the FDA determined that the Company’s remediation activities were effective and its quality management system was adequate.

“Over the last few years, we have made significant investments in both people and processes to enhance our global quality assurance programs,” said Peter Arduini, Integra’s President and Chief Executive Officer. “The lifting of the Warning Letter at our Añasco facility is evidence of the progress we have made in improving our quality systems throughout the Company.”

Please refer to the Form 8-K filed concurrently with this press release for additional information.

Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies, and spine hardware and orthobiologics. For more information, please visit www.integralife.com